Which anticholinergic drug for overactive bladder symptoms in adults
about
Electrical stimulation with non-implanted electrodes for overactive bladder in adultsBeta-3 adrenergic receptor agonist for adult with overactive bladderPelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in womenSurgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunctionOestrogen therapy for urinary incontinence in post-menopausal womenElectrical stimulation with non-implanted electrodes for overactive bladder in adultsAnticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adultsPelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in womenUrodynamic studies for management of urinary incontinence in children and adultsUrodynamic studies for management of urinary incontinence in children and adultsEvaluation and management of overactive bladder: strategies for optimizing careThe efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladderClinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladderOnabotulinumtoxinA for the treatment of overactive bladderThe management of childhood urinary incontinence.CUA guideline on adult overactive bladderEmerging treatments for overactive bladder: clinical potential of botulinum toxins.Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.Electrical stimulation with non-implanted electrodes for overactive bladder in adults.Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United KingdomPostmenopausal overactive bladderCost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.Overactive bladder, differential diagnosis, and clinical utility of fesoterodineNew developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.Overactive bladder - 18 years - Part IIPharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life.Current and future pharmacotherapy for treating overactive bladder.Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis.Augmentation cystoplasty: Contemporary indications, techniques and complications.Pharmacotherapy for Pediatric Neurogenic Bladder.Drugs for the overactive bladder: are there differences in persistence and compliance?A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia.Editorial comment to Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double-blind trial.Testicular Cancer on the Web-an Appropriate Source of Patient Information in Concordance with the European Association of Urology Guidelines?Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controllComparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.Neuropathic pain: A patient-centred approach to measuring outcomes.Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK.
P2860
Q24185932-2992449B-5C25-4B7E-B910-F6DB09E1DB2EQ24187596-D80030C8-7446-4403-BB87-5B9D31F08C8EQ24187989-EDAC4423-B734-47E9-9323-58820E530CD4Q24194577-BDABD663-9A3D-40FE-B288-B91FF1D7E89EQ24198065-A32E3AEE-A931-44CD-8F92-D06E9F672352Q24201215-0C5912FE-6CB0-4A7D-9F6C-5E4BD171F98CQ24202075-7AF94E3A-0DA7-4089-811C-CCEA351E2454Q24202394-C3F49B35-DD7E-4220-BB4B-057616907391Q24202865-3CDA38C3-4902-4779-8E71-CE230EFB51BFQ24203846-E657C39D-0F1E-4145-9D09-2B5450067701Q26739217-8B369AE4-9B14-4178-AB3B-BE2890A6AAAFQ26770419-B9614E95-C374-4802-8530-D0E7724B427DQ26824182-CDD48BC0-C225-48F9-8B77-F46D4D4D4D78Q27002371-85542302-5428-4462-BD66-E9D57F26AC85Q30424701-BD92E70E-9831-45AB-B9BD-4CC1EC5ED46CQ33665026-895B940E-F6B5-4D90-B0C2-37CFEE220B28Q33689757-3DD91B80-876D-48C9-A5BB-6E4AEDAFF53CQ33696642-C6B3FBF1-4609-4F79-B305-70B1D1CF813BQ34546973-3A67A8A9-F53A-44B3-9205-D45A458901CEQ34990256-10E91526-DF89-46F8-A719-BFACF34BBF39Q35157329-8E6EC842-3FDD-4DD9-BC62-ED7FFBF1772CQ35625741-B0301D5E-133E-48D2-941A-4F84B2953959Q36429651-899A12DF-7E58-44F0-B384-FDB7B5A126DDQ36789948-CCF7A134-7959-4107-9F4A-FB371D279E5AQ36912766-2F4CA7EA-1F6C-4C20-9D9A-EE2B5B718CF5Q37390990-C2CE39E3-69F4-444C-9AA3-7AB272EA9598Q38851523-262682BA-C027-48F4-8CA2-5F906DA24B95Q39020998-0794B1E8-761E-40BB-B615-D8AF2BFFF047Q39314841-9A8196EF-3DA8-4E1F-BF9D-8D2717FA143CQ39437361-050620F3-10BC-4CAB-B9E9-BBEFC395B61FQ42332340-ACD92CC4-0A9C-4E1F-8AD5-90D03108EF35Q42565612-A0B8A3A1-95FA-4E0B-9FE6-CF4756013E49Q46690724-275A7424-B3EC-41F2-BA43-6319E03D0D81Q47304965-93D75997-31CD-40A9-B0BA-2E9D751B7640Q47547745-E673EC2E-828C-49CC-8BFB-17BDC6D987ABQ47898713-497A96BB-74B5-4B43-A2D2-C05FFE3B1A84Q52321118-97E6E6F1-627A-4605-8816-BA31CE57FDB5Q54962623-2866E15B-D248-40A8-9945-6CB0C55F792E
P2860
Which anticholinergic drug for overactive bladder symptoms in adults
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Which anticholinergic drug for overactive bladder symptoms in adults
@ast
Which anticholinergic drug for overactive bladder symptoms in adults
@en
Which anticholinergic drug for overactive bladder symptoms in adults
@en-gb
Which anticholinergic drug for overactive bladder symptoms in adults
@nl
type
label
Which anticholinergic drug for overactive bladder symptoms in adults
@ast
Which anticholinergic drug for overactive bladder symptoms in adults
@en
Which anticholinergic drug for overactive bladder symptoms in adults
@en-gb
Which anticholinergic drug for overactive bladder symptoms in adults
@nl
prefLabel
Which anticholinergic drug for overactive bladder symptoms in adults
@ast
Which anticholinergic drug for overactive bladder symptoms in adults
@en
Which anticholinergic drug for overactive bladder symptoms in adults
@en-gb
Which anticholinergic drug for overactive bladder symptoms in adults
@nl
P2093
P2860
P3181
P1476
Which anticholinergic drug for overactive bladder symptoms in adults
@en
P2093
E. Jean C Hay-Smith
G Peter Herbison
Gaye Ellis
June D Cody
Priya Madhuvrata
P2860
P3181
P356
10.1002/14651858.CD005429.PUB2
P577
2012-01-18T00:00:00Z